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Abstract 35 
The contribution of mast cells in the microenvironment of solid malignancies remains controversial. 36 
Here we functionally assess the impact of tumor-adjacent, submucosal mast cell accumulation in 37 
murine and human intestinal-type gastric cancer. We find that genetic ablation or therapeutic 38 
inactivation of mast cells suppresses accumulation of tumor-associated macrophages, reduces 39 
tumor cell proliferation and angiogenesis, and diminishes tumor burden. Mast cells are activated by 40 
interleukin (IL)-33, an alarmin produced by the tumor epithelium in response to the inflammatory 41 
cytokine IL-11, which is required for the growth of gastric cancers in mice. Accordingly, ablation of 42 
the cognate IL-33 receptor St2 limits tumor growth, and reduces mast cell-dependent production 43 
and release of the macrophage-attracting factors Csf2, Ccl3, and Il6. Conversely, genetic or 44 
therapeutic macrophage depletion reduces tumor burden without affecting mast cell abundance. 45 
Therefore, tumor-derived IL-33 sustains a mast cell and macrophage-dependent signaling cascade 46 
that is amenable for the treatment of gastric cancer. 47 
  48 
Page 3 
The interactions between cancer cells and their microenvironment can result in tumor progression 49 
as well as suppression and/or eradication of cancers 1. Besides extracellular matrix and stromal cells, 50 
the tumor microenvironment is composed of immune cells of the adaptive and innate immune 51 
system, with the latter comprising neutrophils, macrophages, mast cells, myeloid-derived suppressor 52 
cells, dendritic cells, innate lymphocytes and natural killer cells. Often T-lymphocytes and tumor-53 
associated macrophages (TAMs) account for the most abundant immune cell populations infiltrating 54 
established tumors 2,3. 55 
 56 
Mast cells are long-lived secretory cells of hematopoietic origin that function as sentinels by 57 
responding to changes in their environment 4. They respond to extrinsic signals through a multitude 58 
of cell surface receptors to secrete histamine and proteases from pre-stored sources in cytoplasmic 59 
granules 5, alongside newly synthesized inflammatory mediators 4. Accordingly, mast cells can be 60 
part of innate and adaptive immune responses and therefore contribute to various 61 
pathophysiological conditions 6. In cancer, the presence of mast cells, both at the tumor periphery  62 
and in the tumor core can correlate with disease progression, increased metastasis and reduced 63 
survival of patients with melanoma 7, prostate cancer 8, pancreatic adenocarcinoma 9, squamous cell 64 
carcinoma 10 and gastric cancer 11,12. However in other solid malignancies, mast cells have been 65 
associated with more favorable outcomes 13-15. The conflicting nature of these correlative findings 66 
are reminiscent of contradictory functional observations in mouse models claiming that mast cells 67 
are required for pancreatic islets tumorigenesis 16, while pancreatic adenocarcinoma occur in a 68 
tumor microenvironment devoid of mast cells 17. 69 
 70 
Interleukin (IL)-33 is a danger-associated signal that can serve as a molecular alarmin when released 71 
upon necroptotic and necrotic cell death including death of cancer cells 18-21. However, cell death-72 
independent IL-33 release can also occur 22,23. IL-33 signals through the heterodimeric ST2 receptor, 73 
encoded by Il1rl1 gene, which is constitutively expressed on the surface of some innate immune cells 74 
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including mast cells 24, innate lymphoid cells type 2 (ILC2) 25 and regulatory T-cells (Treg) 26,27. IL-75 
33/ST2 signaling is involved in triggering innate immune responses upon parasite and viral 76 
infections, and has been identified as an important mast cell activating factor 24,28 in the context of 77 
allergy 29. Furthermore, elevated IL-33 expression was associated with poor outcomes in patients 78 
with gliomas 30, ovarian 31, as well as head and neck cancers 32. However, predicting the outcome of 79 
IL-33/ST2 signaling in malignancies remains uncertain with both tumor promoting as well as tumor 80 
restricting activities being reported in knock-out mouse models 33-36. 81 
 82 
Here, we employ pre-clinically validated mouse models of gastric cancer and corresponding patient 83 
biopsies to functionally elucidate the role of mast cells during gastric tumorigenesis. Our genetic 84 
analysis reveals a linear signaling axis initiated by tumor epithelial-derived IL-33 that activates mast 85 
cells to produce a chemotactic cytokine expression signature. These factors promote the 86 
accumulation of tumor-associated macrophages, which in turn sustain tumor angiogenesis and 87 
growth in mice. In gastric cancer patients, this mast cell activation signature, alongside markers for 88 
tumor-associated macrophages, correlates with decreased patient survival. Our findings delineates a 89 
IL-33/mast cell/macrophage axis, which affords a clinical opportunity for the treatment of gastric 90 
cancer.  91 
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Results 92 
Increased mast cell density in human intestinal-type gastric cancer and in corresponding mouse 93 
models 94 
In order to characterize the role of mast cells in gastric cancer, we initially investigated the mast cell 95 
frequency in gp130FF mice, a pre-clinically validated model for spontaneously occurring intestinal-96 
type gastric cancer 37,38. Gastric tumors in gp130FF mice, which harbor a knock-in germline mutation 97 
in the shared interleukin (IL)-6/IL-11 receptor subunit gp130, arise from excessive IL-6/IL-11 98 
dependent STAT3 activity; these tumors remain associated with chronic inflammation and immune 99 
cell infiltration. We used toluidine blue stains to quantify mast cells, and observed profound 100 
accumulation of mast cells in the submucosa of the gastric antrum in gp130FF mice compared to 101 
wild-type mice. Importantly, mast cells in the submucosa adjacent to gastric tumors were more 102 
abundant than the mast cells in the normal antrum-associated submucosa of gp130FF mice (Fig. 1a, 103 
b). In addition, mast cell numbers in gp130FF;Stat3+/- compound mutant mice, which neither develop 104 
gastric tumors nor the other pan-inflammatory changes observed in their Stat3-proficient 105 
gp130FF;Stat3+/+ littermates 39,40, remained comparable to those in wild-type mice. 106 
 107 
To ascertain that submucosal mast cell accumulation correlated with tumorigenesis independently 108 
of the nature of the oncogenic driver mutation, we also assessed mast cell distribution in Tg(Tff1-109 
CreERT2);Pik3caH1047R/+;Ptenfl/fl mice. In this model, conditional activation of a pan-glandular gastric 110 
epithelium-specific Cre-recombinase induces aberrant activation of phosphatidylinositol 3-kinase 111 
(PI3K), a pathway frequently mutated in human gastric cancer. Akin to our observations in gp130FF 112 
mice, mast cells also accumulated in the submucosa of tumors in Tg(Tff1-113 
CreERT2);Pik3caH1047R/+;Ptenfl/fl mice (Supplementary Fig. 1a, b). Strikingly, Toluidine blue, Alcian 114 
Blue/Safranin-O and May-Grunwald-Giemsa stains for granular content all consistently revealed that 115 
mast cells localized to the submucosal layers of the antrum and body of the stomach, rather than 116 
within the tumors (Supplementary Fig. 1c).  117 
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We next assessed the stromal abundance of mast cells in human biopsies collected from patients 118 
with either histopathologically classified diffuse or intestinal-type gastric cancer, or patients with 119 
pre-neoplastic intestinal metaplasia or chronic gastritis. Similar to our observation in mice, we 120 
observed a profound submucosal accumulation of toluidine-blue positive mast cells in intestinal-type 121 
gastric cancer. Strikingly, mast cells numbers were not elevated in the submucosa of patients with 122 
gastritis or intestinal metaplasia (Fig. 1c, d). Collectively, our results show increased mast cell 123 
abundance in the tumor-adjacent submucosa of intestinal-type gastric adenocarcinoma in human 124 
and mice, irrespective of the nature of the oncogenic driver mutation(s).  125 
 126 
Mast cell deficiency diminishes gp130FF-driven tumor growth 127 
Having established a reproducible correlation between submucosal mast cell density and gastric 128 
cancer in humans and mice, we next determined the functional role of mast cells during tumor 129 
initiation and progression. For this we exploited the gp130FF model because of its high disease 130 
concordance with the human GC subtype, reproducible penetrance, onset and progression of gastric 131 
tumorigenesis.  132 
 133 
In order to establish whether submucosal mast cell accumulation preceded tumorigenesis, we 134 
analyzed stomach sections of 4-week old gp130FF mice prior to onset of tumor formation. We 135 
detected increased mast cell density in the gastric submucosa of these tumor-free gp130FF mice 136 
when compared to the submucosa of age-matched WT littermates (Supplementary Fig. 2a). To 137 
functionally determine whether mast cells indeed promote gastric tumor growth, we crossed 138 
gp130FF mice with mast cell-deficient C57BL/6 c-KitW-sh/W-sh mice carrying an inversion of the 5’-139 
regulatory region of the c-Kit gene that results in hypomorphic expression of the corresponding stem 140 
cell factor receptor protein. Accordingly, c-KitW-sh/W-sh mice exhibit a substantial reduction of mast 141 
cells in all tissues 41-43, but do not suffer from anemia, sterility and lethality associated with complete 142 
c-Kit deficiency 41. Likewise, we did not observe differences in the peripheral blood composition 143 
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between gp130FF and gp130FF;c-KitW-sh/W-sh compound mutants and we confirmed that EpCAM 144 
positive tumor cells lack c-Kit expression (Supplementary Figs. 2b, c). However, gp130FF;c-KitW-sh/W-sh 145 
compound mice had significantly smaller and fewer tumors than their age and sex-matched gp130FF 146 
littermates (Fig. 2a-c). This reduction in tumor burden coincided with reduced tumor cell 147 
proliferation rather than increased apoptosis, and was associated with a reduction of CD31+ 148 
endothelial cells (Fig. 2d and Supplementary Fig. 2d).  149 
 150 
To exclude that the anti-cancer effect of the c-KitW-sh hypomorphic allele was not in part mediated by 151 
hematopoietic cells other than mast cells, we generated mast cell-deficient gp130FF;Cpa3-152 
Cre;Mcl1fl/fl gastric cancer mice, where mast cell-specific carboxypeptidase A3 (Cpa3) promoter 153 
driven Cre-recombinase activity leads to the deletion of Mcl1 pro-survival gene. As a consequence 154 
Cpa3-Cre;Mcl1fl/fl mice retain less than 10%  mast cells and have reduced numbers of basophils, 155 
while all other hematopoietic cell populations remain unaffected 44. We confirmed that 156 
gp130FF;Cpa3-Cre;Mcl1fl/fl mutant mice lack mast cells in their stomachs, while their gp130FF;Cpa3-157 
Cre;Mcl1+/+ littermates display normal mast cell density (Supplementary Fig. 2e). Importantly, mast 158 
cell-deficient gp130FF;Cpa3-Cre;Mcl1fl/fl mice had significantly reduced tumor mass and tumor 159 
number compared to their mast cell-proficient controls (Fig. 2e, f), and this observation coincided 160 
with reduced angiogenic vessel density in the tumors of gp130FF;Cpa3-Cre;Mcl1fl/fl mice (Fig. 2g).  161 
 162 
To assess whether therapeutic mast cell manipulation could reduce the burden of established 163 
tumors, we exploited sodium cromoglycate (cromolyn) as a blocking agent for mast cell 164 
degranulation in patients. We treated tumor-bearing gp130FF mice for six weeks with cromolyn, 165 
which significantly decreased tumor burden when compared to vehicle-treated mice 166 
(Supplementary Fig. 2f and Fig. 2h). Akin to our observations genetic observations in gp130FF;c-KitW-167 
sh/W-sh and gp130FF;Cpa3-Cre;Mcl1fl/fl mice, cromolyn treatment of gp130FF mice also reduced 168 
macrophage accumulation, tumor angiogenesis and proliferation (Supplementary Fig. 2g). These 169 
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findings demonstrate the importance of mast cells and their released products for gastric tumor 170 
growth and suggest that mast cells promote tumor proliferation through mechanisms involving 171 
angiogenesis.  172 
 173 
In the gp130FF mutant mice all cells harbor the gp130F mutation. When expressed, the gp130F 174 
mutant protein increases Stat3 signaling in response to IL-6 family cytokines. Because mast cells 175 
express the gp130 co-receptor and can respond to IL-6 family cytokines 45,46, we next excluded the 176 
possibility that the gp130F allele in mast cells may augment their tumor-promoting ability. For this, 177 
we reconstituted the hematopoietic compartment of six week-old lethally irradiated gp130FF hosts 178 
with the bone marrow from WT (gp130+/+) or gp130FF mice (Supplementary Fig. 2h). Indeed, WT-> 179 
gp130FF and gp130FF-> gp130FF bone marrow chimeras showed not only similar mast cell frequencies 180 
in the gastric submucosa, but also comparable tumor burden, and macrophage infiltration in the 181 
submucosa and tumor core (Supplementary Fig. 2i). These results indicate that the systemic 182 
presence of the gp130FF mutation did not skew hematopoietic cells towards a tumor-promoting role, 183 
nor did it increase the mast cell abundance within the gastric tumor microenvironment.  184 
  185 
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Macrophages are reduced in gastric tumors in a mast cell-dependent manner  186 
Because we observed mast cells outside of the tumor cores, we surmised that tumor-promoting 187 
effect of mast cells might occur indirectly by affecting the composition and/or function of tumor 188 
infiltrating immune cells. We therefore enumerated tumor-free and tumor-containing stomach 189 
sections collected from gp130FF and mast cell-deficient gp130FF;c-KitW-sh/W-sh mice for the F4/80 190 
macrophage, CD3 T lymphocyte and B220 B-lymphocyte markers. While we observed a 30% 191 
reduction in macrophage frequency in the submucosa and cores of tumors from gp130FF;c-KitW-sh/W-sh 192 
mice, the lymphocyte (CD3+), Treg (Foxp3+) and CD8+ T cell frequencies remained unchanged (Fig. 3a, 193 
b). Reduced macrophage abundance within the tumor core and sub-mucosa was also observed in 194 
the mast cell-deficient gp130FF;Cpa3-Cre;Mcl1fl/fl mice (Fig. 3c) and cromolyn-treated gp130FF mice 195 
(Supplementary Fig. 2g). Because genetic or pharmacological interference with mast cells not only 196 
inhibited tumor growth, but concomitantly also reduced the abundance of tumor associated 197 
macrophages, we postulate that a hierarchical mast cell – macrophage relationship underpins the 198 
growth of gastric cancer. 199 
 200 
Macrophage-infiltration coincides with gastric tumorigenesis  201 
To ascertain that the accumulation of tumor associated macrophages was a common occurrence for 202 
intestinal-type gastric cancers, we assessed macrophages density in the submucosa and mucosa of 203 
tumor-bearing gp130FF and Tg(Tff1-CreERT2);Pik3caH1047R/+;Ptenfl/fl mice. We noted an increased 204 
abundance of macrophages in the submucosa and the mucosa of either model (Fig. 3d, e and 205 
Supplementary 3a, b), consistent with the increased abundance of submucosal mast cells in both 206 
models (Fig. 1a, b and Supplementary Fig. 1a, b). To establish whether the increased macrophage 207 
accumulation occurs prior to tumor formation, akin to our observations with mast cells, we analyzed 208 
naïve gp130FF mice at 4-weeks of age. In these mice macrophage numbers were increased in the 209 
submucosal layers, but remained similar between the precancerous mucosa of gp130FF and of WT 210 
mice (Supplementary Fig. 3c, d). Collectively, these findings positively correlate macrophage 211 
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numbers with gastric tumor growth and suggest a potential macrophage contribution to tumor 212 
formation and progression.  213 
 214 
Macrophages are required for gastric tumorigenesis in gp130FF mice  215 
Macrophages have been established as drivers of tumor growth and cancer therapy targets for 216 
several tumor entities 47,48. To formally investigate a functional contribution of macrophages to 217 
gastric tumorigenesis, we generated macrophage-deficient gp130FF;Csf1r-/- mice, because expression 218 
of the Csf1r gene and its corresponding receptor protein for macrophage colony-stimulating factor is 219 
required for maturation of bone marrow-derived macrophages from their monocytic precursors. 220 
Strikingly, the few surviving gp130FF;Csf1r-/- mice remained completely free of gastric tumors (Fig. 4a, 221 
b). The submucosal mast cell density was not altered in the macrophage-deficient animals (Fig. 4c). 222 
We next confirmed that this phenotype reversion was not related to the runted phenotype of 223 
gp130FF;Csf1r-/- mice associated with their feeding requirement for mashed chow to overcome the 224 
Csf1R deficiency-dependent absence of teeth. We therefore depleted macrophages in adult tumor-225 
bearing gp130FF mice by systemic administration of clodronate-loaded liposomes (clodrosomes) for 226 
six consecutive weeks and observed a significant reduction of tumor burden when compared to the 227 
vehicle control cohort (Fig. 4d). Although toluidine-staining confirmed that clodrosome treatment 228 
did not reduce the abundance of submucosal mast cells, gastric tumors and adjacent submucosa 229 
from the clodrosome cohort revealed reduced density of CD31-positive microvessels (Fig. 4e and 230 
Supplementary Fig. 4a).  231 
 232 
The reduced tumor-burden and microvessel density observed in the clodronate cohort were similar 233 
to our findings from the mast-cell depletion experiments. We next aimed to exclude that they relate 234 
to off-target-effects associated with bisphosphonate (i.e. clodronate) administration. We therefore 235 
treated tumor-bearing gp130FF mice with the small molecule Csfr1/c-kit/Flt3 kinase inhibitor 236 
PLX3397 (Pexidartinib). We supplied PLX3397 in the food to tumor-bearing gp130FF mice for four 237 
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weeks (acute therapeutic) and continued a cohort for a further four weeks without PLX3397 238 
treatment (follow-up) (Supplementary Fig. 4b). Acute PLX3397 treatment revealed a significant 239 
reduction in tumor burden, although this anti-tumoral effect was reversible as the tumor burden 240 
increased once PLX3397 treatment ceased in the follow-up cohort (Fig. 5a). In the acute treatment 241 
cohort, we confirmed by immunohistochemical staining a significant reduction of F4/80-positive 242 
macrophages accompanied by reduced density of CD31-positive angiogenic vessels and increased 243 
staining for tumor-hypoxia (Fig. 5b and Supplementary Fig. 4c). However, owing to the specificity of 244 
PLX3397, we also observed a decrease of tumor-adjacent submucosal mast cells. All these 245 
parameters reverted back to their pre-treatment state following a drug-free period in the follow-up 246 
cohort (Supplementary Fig. 4c).  247 
 248 
Based on our proposed role for macrophages to mediate the tumor promoting effect of mast cells, 249 
we hypothesized that the tumor associated macrophages in the gastric lesions of gp130FF mice 250 
should have a tumor-promoting alternatively activated endotype. We therefore compared 251 
expression of macrophage endotype markers between naïve bone marrow-derived macrophages 252 
(BMM) and tumor associated macrophages, and used standard in vitro polarization protocols for 253 
BMM to generate a reference population for alternative activation. For the tumor associated 254 
macrophage populations, this analysis revealed high expression of the alternative activation markers 255 
Arg1, Fizz1 and Mrc1, which coincided with reduced mRNA levels of the classically activated marker 256 
Nos2 (Fig. 5c). Consistent with the pronounced presence of microvasculature in tumors of these 257 
gp130FF mice, we also recorded elevated expression of angiogenic Vegfa in the tumor associated 258 
macrophage population when compared to the naïve BMM population from the same mice (Fig. 5c). 259 
Given the alternative activated endotype of tumor-associated macrophages, our data collectively 260 
suggests that their abundance is likely to be a rate-limiting factor for the establishment of tumor 261 
microvasculature and the growth of gastric tumors. 262 
  263 
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Tumor-derived IL-33 activates mast cell secretion and expression of macrophage-attracting 264 
chemokines 265 
Although our observations thus far suggested a functional mast cell - macrophage relationship, it 266 
remained to determine the molecular network underpinning this hierarchy including how its 267 
activation could occur. We therefore focused on IL-33 as a potential tumor-derived activator of mast 268 
cells, because IL-33 was reported to serve as an alarmin that is generated and released by necrotic 269 
cells, and that triggers mast cell degranulation 49. Indeed, we detected increased expression of Il33 in 270 
the EpCam+/CD45- epithelial components of the tumors in gp130FF mice with a reciprocal expression 271 
of the Il1rl1 gene in the hematopoietic CD45+/EpCam- compartment of the antrum, which encodes 272 
the cognate St2 receptor subunit for IL-33 (Fig. 6a). In line with the reported storage of IL-33 protein 273 
in vesicles, we detected increased levels of Il33 mRNA and IL-33 protein in whole tumor tissue 274 
(Supplementary Figs. 5a, b). Immunofluoresence staining revealed that IL-33 protein localized most 275 
prominently to the peripheral regions of the epithelial components of the tumors (Fig. 6b) coinciding 276 
with the location of the highest level of cellular turn-over 37. 277 
 278 
To assess whether tumor associated mast cells could respond to IL-33, we FACS purified the c-279 
Kit+/FcεR1+ mast cells from the submucosal antrum of WT and gp130FF mice using stomachs from 280 
gp130FF;c-KitW-sh/W-sh mice as a specificity control for our purification strategy (Supplementary Fig. 281 
5c). We confirmed the homogeneity of the c-Kit+/FcεR1+ mast cell population by Toluidine blue 282 
staining (Supplementary Fig. 5d) and showed prominent expression of the St2 receptor in the c-283 
Kit+/FcεR1+ mast cells isolated from the stomach of gp130FF mice (Supplementary Fig. 5e). We then 284 
stimulated this cell population for 3 hour with IL-33 and detected by multiplex cytokine assay 285 
increased amounts of IL-6 and IL-13 and to lesser extent of IL-1α, IL-4, alongside elevated secretion 286 
of the macrophage growth and attracting factors Gm-csf, Mcp1, Mip-1α and Mip-1β (Supplementary 287 
Fig. 5f and Fig. 6c). Likewise, qPCR analysis of the IL-33 stimulated mast cells also revealed increased 288 
expression of Ccl2 (encoding Mcp1 protein), Ccl3 (encoding Mip-1α protein) and Ccl7 (Fig. 6d), which 289 
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collectively exert chemotactic activity towards macrophages and neutrophils 50-52. Also, IL-33-290 
stimulation induced elevated expression of angiogenic growth factor gene Vegfa (Fig. 6d). In order to 291 
confirm the chemotactic activity of the mast cell produced factors on gp130FF macrophages, we 292 
performed migration assays with bone marrow derived macrophages. Indeed, Mcp1 and Mip-1α 293 
alone induced migration significantly (Supplementary Fig. 5g). 294 
 295 
Because gp130FF-driven gastric tumorigenesis has an absolute requirement for IL-11 signaling 53, we 296 
predicted that IL-11 could stimulate IL-33 expression in tumor-derived epithelium. To test this, we 297 
exposed epithelial organoids grown from gp130FF-tumors to recombinant IL-11 in vitro. While 298 
organoid growth and morphology were not altered (Fig. 6e and Supplementary Fig. 5h), we observed 299 
a marked increase in Il33 expression upon IL-11 stimulation, which was comparable to the extent of 300 
induction of the bona fide IL-11/Stat3 target gene Socs3 (Fig. 6f). Additionally, we conducted a 301 
chromatin immunoprecipitation (ChIP) experiment on DNA from gastric tumors of gp130FF mice 302 
60min after acute systemic administration of IL-11. The CHIP experiment revealed a Stat3-specific 303 
binding peak on chromosome 19, which maps to the 5’-region of the Il33 gene and which contains a 304 
Stat3-binding site motif (Supplementary Figs. 5i, j). Collectively, these data indicate that tumor-305 
derived IL-11 induces Il33 gene expression in gastric tumor cells, which triggers the secretion as well 306 
as the de novo synthesis of cytokines and chemokines by mast cells to produce a tumorigenic 307 
immune environment.  308 
 309 
 IL-33/St2 signaling deficiency decreases gp130FF-mediated gastric tumor growth 310 
To validate a functional contribution of IL-33 signaling as a master regulator of mast cell activation in 311 
the gastric tumor microenvironment, we generated IL-33 signaling deficient gp130FF;St2-/- mice. 312 
Compared to their St2+/+ and St2+/--proficient compound mutant littermates, gp130FF;St2-/- mice 313 
harbored a significantly lower overall tumor burden at 100 days of age (Fig. 7a), which arose from 314 
reduced tumor growth rather than reduced tumor incidence (Fig. 7b). These observations coincided 315 
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with a decrease in mast cell numbers in the tumor-adjacent submucosal layers and reduced density 316 
of F4/80+ macrophages in the tumors of gp130FF;St2-/- mice as well as reduced abundance of CD31-317 
positive microvessels (Fig. 7c). 318 
We next confirmed that c-Kit+/FcεR1+ mast cells isolated from gp130FF;St2-/- mice showed 319 
significantly decreased expression of the macrophage recruiting and inflammatory mediators Csf2 320 
(encoding Gm-csf), Ccl3, and Il6 (Fig. 7d). Because IL-33 signaling is involved in expansion and 321 
activation of ILC2 and Tregs, which could also afford a mechanism for IL-33 to promote gastric 322 
tumorigenesis in gp130FF mice, we assessed the relative abundance of ILC2 and Tregs among all cells 323 
harboring the pan-hematopoietic surface marker CD45. We observed comparable frequency of 324 
these cells between unaffected antrum and tumors of gp130FF and gp130FF;St2-/- mice. Moreover, 325 
less than 30% of all tumor-associated ILC2 cells, and less than 15% of all Tregs, expressed the St2 326 
receptor (Fig. 7e, f). 327 
To investigate the involvement of mast cells in the anti-tumoral effect of St2-deficiency, we 328 
established bone marrow-derived mast cells (BMMC) from gp130FF;ST2-/- and gp130FF;St2+/+ mice, 329 
confirmed their purity (Supplementary Figs. 6a-c) and performed adaptive transfer of BMMC into 330 
gp130FF;St2-/- hosts (Supplementary Fig. 6d). Reconstitution with St2+ wild-type BMMC 331 
(gp130FF;St2+/+) increased tumor burden compared to littermates injected with gp130FF;St2-/- BMMCs 332 
(Fig. 7g and Supplementary Fig. 6e). At the time point of tumor analysis 8% of the gastric submucosal 333 
mast cells stained positive for St2 expression and therefore represent the transplanted BMMC mast 334 
cells, which homed to the gastric tumor site and compete with the endogenous ST2-/- mast cell 335 
compartment (Supplementary Fig. 6f). 336 
These observations further support a mechanism by which IL-33 promotes gastric tumorigenesis 337 
through mast cell activation rather than by promoting ILC2 or Treg accumulation. 338 
 339 
IL-33/mast cells-activity gene expression signature predicts poor survival for human intestinal-type 340 
gastric cancer 341 
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In order to translate our preclinical findings in mice to a relevant setting in humans, we hypothesized 342 
that the extent of mast cell activation might provide retrospective prediction of patient survival. 343 
Based on the mast cell activation gene expression signature derived from our in vitro mast cell 344 
stimulation with IL-33, we analyzed a publically available data set (DErrico Gastric data set; GEO: 345 
GSE13911) for differential expression of the mast cell signature comprising CCL2, CCL3, CCL4, IL1a, 346 
IL4, IL6, IL13, CSF2, and CCL7. With the exception of IL-4 and IL-13, we found that all other factors 347 
were at least 1.6-fold increased in the cancer samples (p ≤ 0.05) (Fig. 8a). We therefore assigned the 348 
differentially expressed factors (i.e. CCL2, CCL3, CCL4, IL1a, IL6, CSF2 and CCL7) to an IL-33/mast cell 349 
activation gene expression signature for a Kaplan-Meyer survival analysis (KMplot.com) 54. 350 
Remarkably, we found a lower overall survival for intestinal-type gastric cancer patients with high 351 
expression of the entire signature (HR=1.61; logRank P = 0.043) (Fig. 8b). Similar to our IL-33/mast 352 
cell activation gene expression signature, a trend for better survival probability was found for high 353 
expression of a classical mast cell marker gene signature consisting of KIT, FCER1G and HDC 354 
(encoding Histidine Decarboxylase) (HR=1.42; logRank P = 0.067) (Supplementary Fig. 7a) as well as 355 
for ST2-receptor encoding gene IL1RL1 (HR=1.57; logRank P = 0.049) (Supplementary Fig. 7b). In 356 
accordance with our mast cell – macrophage hierarchy model, Kaplan-Meyer survival analysis for 357 
macrophages revealed a survival disadvantage for intestinal-type gastric cancer patients with high 358 
expression of an alternatively activated macrophage gene signature (Fig. 8c). On the other hand, 359 
high expression of a classically activated gene signature correlates with a higher survival probability 360 
(Fig. 8d). Our preclinical data argue strongly for a tumor promoting role of a signaling axis emanating 361 
from IL-11-induced, tumor cell-derived IL-33 and the subsequent hierarchical activation cascade of 362 
mast cells and tumor associated macrophages. Collectively, these innate immune cells enable the 363 
establishment of the microvasculature required for gastric tumor growth and may provide 364 
therapeutically actionable targets (Fig. 8e). 365 
  366 
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Discussion 367 
Although conflicting data indicate a dichotomous role of mast cells to either restrict or support 368 
tumorigenesis, compelling evidence implicates mast cells in promoting progression and metastasis in 369 
many solid malignancies. Retrospective studies on human gastric cancers have suggested an 370 
involvement of tumor-adjacent submucosal mast cells to late stage disease 55 and metastasis 371 
formation 12. However, the molecular mechanism by which submucosal mast cells contribute to 372 
gastric tumorigenesis, and indeed early stage tumorigenesis, is not understood. Here we 373 
demonstrate that submucosal accumulation of mast cells in two independent murine models of 374 
intestinal-type gastric cancer functionally contributes to tumorigenesis and the maintenance of 375 
established tumors and that this coincides with the presence of alternatively activated pro-376 
tumorigenic tumor associated macrophages. We provide evidence that tumor cell-derived IL-33 377 
stands on the apex of a cascade by which mast cells, through recruitment of tumor associated 378 
macrophages and their support of a vascular network, ensures the growth and maintenance of 379 
gastric tumors. Indeed, ablating mast cells or macrophages in tumor-bearing mice either individually  380 
with cromolyn or clodrosomes, or together with PLX3397, was associated with a vascular collapse 381 
and tumor hypoxia. Importantly, we support the relevance of our functional findings in mice with a 382 
correlation in humans where a mast cell activation signature associates with poor patient outcome 383 
for intestinal-type gastric cancer.  384 
 385 
Within the tumor microenvironment, myeloid cells are among the most important innate immune 386 
cells that promote tumor formation and restrict the effect of many forms of therapy, most notable 387 
immunotherapy 56. In particular the plasticity of tumor associated macrophages has attracted 388 
interest as therapeutic opportunities to limit the angiogenic and immune suppressive functions 389 
conferred by their alternatively activated endotype 3. On the other hand, mast cells have been 390 
proposed to be an abundant source of VEGF, TGFβ and other angiogenic factors, as well as matrix 391 
metalloproteinase 9 and related stromal remodeling enzymes 57. Indeed, mast cells are one of the 392 
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earliest cell types recruited into the tumor microenvironment 11,58, and progression of gastric cancer 393 
correlates with both, the accumulation of chymase-positive mast cells and increased microvascular 394 
density 11,59. Functionally, these observations are mirrored by an angiogenic switch proposed to be 395 
orchestrated by mast cells during early stages of pancreatic cancer in mice required for the extensive 396 
vascular elaboration to prevent hypoxia during expansion of tumors 16. Surprisingly, the authors in 397 
this early study had argued against a role for macrophages in mast cell-dependent induction of early 398 
tumor angiogenesis, based on their observations that macrophage recruitment to pancreatic islets 399 
remained unaffected by mast cell deficiency. Indeed, our observations that IL-33 result in the 400 
induction of Vegfa expression in isolated mast cells supports this view and this is corroborated by 401 
reduced microvessel density in tumors of gp130FF;St2-/- mice. However, our observations presented 402 
here following either genetic ablation of mast cells or macrophages, or their respective 403 
pharmacological inhibition by cromolyn and clodronate or PLX3397 strongly suggest that the 404 
endothelial cell support provided by mast cells also depends in part on the recruitment of 405 
macrophages. 406 
 407 
Because we functionally link tumor growth to the presence of mast cells in two independent genetic 408 
models, it is highly unlikely that this arises from independent serendipitous effects of the two 409 
models other than mast cells. Thus, it is highly likely that the incompletely understood mechanisms 410 
by which cromolyn blocks mast cell degranulation mediated the anti-tumor effect observed here, 411 
rather than cromolyn also affecting monocytes, the production of the neutrophil product 412 
myeloperoxidase, and circulating growth 60. Akin to tumor associated macrophages being induced by 413 
tumor cells to adopt an alternatively activated endotype optimized for wound-healing, neoplastic 414 
epithelia appears to also corrupt the wound-healing function of mast cells to facilitate tumor growth 415 
56. Accordingly, tumor cell-specific over-expression of the master-regulator c-Myc not only results in 416 
epithelial hyper-proliferation (when coinciding with increased expression of BH3 survival proteins), 417 
but also in expression of chemo-attracting CCL2, CCL3 and CCL5 and concomitant accumulation of 418 
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mast cells 16. Here we identify a second mechanism that depends on the IL-1 cytokine family 419 
member IL-33, which acts as a chief regulator of innate immunity and inflammation, and maintains 420 
epithelia barrier functions of the intestine. Indeed, IL-33 serves a bona fide alarmin and is released 421 
by damaged epithelium as an endogenous danger signal to activate innate immune responses 28. 422 
Accordingly, mast cells and ILC2s respond through the IL-33/ST2 axis to the damaged intestinal 423 
mucosa arising from acute injury or infection. Therefore mast cells are found at sites of epithelial 424 
recovery 61, and ILC2 cells release IL-13 to stimulate the intestinal stem cell compartment, 425 
respectively 62. Intriguingly, our experimental lines of evidence from tumors of gp130FF;St2-/- mice 426 
shows that their reduced tumor burden correlates with decreased mast cell frequency rather than a 427 
change in ILC2 abundance. While not ruling out minor contributions by ILC2, regulatory T-cells or 428 
other IL-33 responsive cells, the increased tumor mass in gp130FF;St2-/- mice following adoptive 429 
transfer of St2-proficient mast cells, provides definitive functional evidence that mast cells act as the 430 
major cell population through which IL-33 promotes tumor growth.  Accordingly tumor growth of 431 
gp130FF mice was susceptible to the highly mast cell-selective cellular deficiency in gp130FF;Cpa3-432 
Cre;Mcl1fl/fl mice, or to cromolyn-dependent inhibition of mast cell degranulation. Meanwhile, and 433 
consistent with the capacity of IL-33 to promote tissue repair and wound healing, IL-33 can also 434 
mediate metaplasia of the gastric epithelium 63. 435 
 436 
Although epithelial cells of barrier tissues exposed to the environment are major sources of IL-33, 437 
and IL-33 expression is further increased during inflammation and in the tumor epithelium 64, the 438 
exact nature of the factors that induce IL-33 expression and its release remain unclear. For instance 439 
TNF, IL-1β, TGFβ, prostaglandins, lipopolysaccharides and other pathogen-associated molecular 440 
patterns have all been suggested as drivers for IL-33 expression during intestinal adenomatous 441 
polyposis 65-67. Here, we provide evidence for IL-33 expression in gastric tumor epithelium to also be 442 
stimulated by an IL-11/Stat3 signaling cascade, which we and others have identified as an absolute 443 
requirement for effective growth of gastrointestinal tumors. However, at this stage we can only 444 
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speculate that sub-epithelial myofibroblasts and possibly tumor-associated endothelial cells, which 445 
have been proposed as sources of IL-11 68, may also contribute to epithelial expression of IL-33. 446 
Furthermore, because mast cells express gp130, we could not formally exclude the possibility that 447 
the presence of the hypermorphic gp130F allele in mast cells may promote their proliferation and 448 
survival 46, as this receptor allele augments Stat3 signaling in response to IL-6 family cytokines. 449 
However, we noted similar submucosal mast cell accumulation adjacent to tumors in gp130FF and in 450 
Tg(Tff1-CreERT2);Pik3caH1047R/+;Ptenfl/fl mice, where the latter cohorts express WT gp130. Likewise, 451 
reconstitution of gp130FF mice with WT bone marrow did not affect mast cell numbers and tumor 452 
burden, as would be expected if the gp130F allele augmented mast cell activity. 453 
 454 
Therapeutic inhibition of IL-33 signaling is gaining interest with anti-ST2 antibodies being trialed for 455 
asthma. Given the dichotomous activity of IL-33 in tumor biology, timing of anti-IL-33 signaling 456 
therapy will be crucial. In the context of gastric cancer, mast cells may not only promote metastasis, 457 
but also modulate the immunosuppressive tumor environment through the release of IL-17 69. Thus, 458 
IL-33 signaling provides a target to restrict the tumor promoting activities of the myeloid 459 
compartment and may ultimately enable rational combination therapies to alleviate the activity by 460 
which myeloid cells limit the anti-tumor immune response. The linear signaling cascade identified 461 
here comprising IL-11/IL-33/Mast cells/Macrophages/Tumor cells should provide complementary 462 
molecular and cellular targets for the development of improved cancer therapies. 463 
  464 
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Methods 465 
Study approval 466 
All animal studies were conducted in accordance with all relevant ethical regulations for animal 467 
testing and research including the Australian code for the care and use of animals for scientific 468 
purposes. All animal studies were approved by the Animal Ethics Committee of the Ludwig Institute 469 
for Cancer Research, the Walter and Eliza Hall Institute of Medical Research, or Austin Health.  470 
We have complied with all relevant ethical regulations for work with human participants. Collection 471 
and usage of human gastric cancer tissues was approved by the Peter MacCullum Cancer Center 472 
ethics committee and informed consent was obtained from all subjects. 473 
 474 
Mice  475 
Knockin mice (gp130Y757F/Y757F, alias gp130FF mice), the compound mutants strains gp130FF;Stat3+/– 476 
39,40 and Tg(Tff1-CreERT2);Pik3caH1047R/+;Ptenlox/+ as well as wild type control mice were bred on a 477 
mixed C57B6 × 129/Sv background. gp130FF;c-KitW-sh/W-sh 41, gp130FF;Csf1r-/-  70 and gp130FF;St2-/- mice 478 
71, knockout of the Il-33 receptor (encoding gene name: Il1rl1), gp130FF;Cpa3-Cre;Mcl1lox/lox 44 (mast 479 
cell-deficient gp130FF compound mutant mice) were maintained on a C57B6 background. 480 
Tg(Tff1-CreERT2);Pik3caH1047R/+;Ptenlox/+ compound mutant mice were established , where mutant 481 
allele induction is induced by the Tff1-CreERT2 transgene and is specific for the gastric epithelium of 482 
the stomach 72. 483 
gp130FF mice used in the PLX-treatment experiment were propagated on a C57B6 background.  484 
Co-housed, age- and gender-matched littermates were utilized for all experiments. All strains were 485 
housed under specific pathogen–free conditions. 486 
 487 
Human gastric cancer tissue 488 
Human gastric cancer tissue micro arrays (TMA) were used to identify Toluidine Blue –stained mast 489 
cells in gastric disease. TMA were established previously 73. In short, formalin-fixed paraffin-490 
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embedded gastric tissue samples we selected, pathology was confirmed by independent pathology 491 
review and 0.6mm punches were re-embedded to generate the TMA. Usage of human gastric 492 
cancer tissues was approved by the Peter MacCullum Cancer Center ethics committee and 493 
informed consent was obtained from all subjects. 494 
 495 
Inhibitors and treatment regimes 496 
Cromolyn sodium salt (referred to as cromolyn; Sigma-Aldrich, Cat# C0399) is a clinically approved 497 
mast cell-degranulation inhibitor 74. Cromolyn was dissolved in phosphate buffered saline (PBS) and 498 
administered at a concentration of 75 mg/kg bodyweight via the intra peritoneal route (100 µl) three 499 
times per week for 6 consecutive weeks. Control cohorts received PBS. 500 
 501 
Clodronate, formulated as liposome-loaded clodrosomes (containing 5 mg clodronate per 1 ml of 502 
clodrosome suspension), were injected intraperitoneal as 50 µl clodrosomes suspension twice per 503 
week for 6 consecutive weeks. Liposomes containing suspension was injected as placebo in control 504 
mice.  505 
 506 
The csf1r/c-kit/Flt3-specific inhibitor PLX3397 (Plexxicon), supplied at 800 mg PLX3397 per kg of 507 
chow, was given to mice for 4 consecutive weeks represents an estimated dose of 100 mg per kg 508 
body weight daily. Vehicle cohorts received unmanipulated chow. For the follow-up cohorts, mice 509 
were kept for 4 weeks on unmanipulated chow following their 4 week treatment period. 510 
 511 
Tissue preparation and processing 512 
Tumors and adjacent antral tissues were resected and weighed and then snap-frozen for RNA or 513 
protein isolation. Entire stomachs were removed and fixed in 10 % neutral buffer formalin for 514 
histological analysis 39. 515 
 516 
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Histological and immunohistochemical analysis 517 
Hematoxylin-Eosin, Toluidine blue, Alcian blue, Safranin O and May-Grünwald-Giemsa staining of 518 
formalin-fixed paraffin-embedded stomach slides were performed according to Theory and practice 519 
of histological technique from JD Bancroft 75.  520 
For in vivo assessment of proliferation by anti-BrdU staining, tissues were collected 2 hours after i.p. 521 
injection of 50 mg/kg BrdU (Amersham Biosciences, GE Healthcare). Staining’s for apoptosis (Cell 522 
Death Detection Kit, Roche) and tissue hypoxia (60 mg/kg HP1 i.p. injection 30min prior to tissue 523 
collection, detection with Hypoxyprobe-1 Kit, from Hypoxyprobe Inc., USA) were performed 524 
according to manufacturers’ instructions.  525 
All other immunostaining procedures were conducted as follows. For antigen-retrieval, paraffin-526 
embedded sections were either heated in citrate buffer in a microwave pressure cooker (pH 6 for 15 527 
minutes) or were incubated in 0.1 % trypsin, 3 % acetic acid solution at 37 degree for 10 minutes. 528 
Sections were then blocked in 10 % (v/v) normal goat serum for 1 hour at room temperature. 529 
Primary antibodies were diluted in 10 % (v/v) normal goat serum and incubated overnight at 4 oC in a 530 
humidified chamber. Biotin-labeled secondary antibodies from the Avidin Biotin Complex ABC-kit 531 
(Vector Laboratories) were used according to the manufacturer’s instructions. Visualization was 532 
achieved using 3,3-Diaminobenzine (DAB, DAKO). Images were generated with Aperio ImageScope 533 
v11.2.0.780 software. Primary antibodies used: rabbit anti-mouse CD31 (1:200 dilution, Abcam, Cat# 534 
28364, RRID: AB_726362), rat anti-mouse F4/80 (1:200 dilution, Abcam, Cat# 6640, RRID: 535 
AB_1140040), rat anti-mouse B220 (1:200 dilution, BD Biosciences, Cat# 550286, RRID:AB_393581), 536 
rabbit anti-mouse CD3 (1:200 dilution, Abcam, Cat# ab5690, RRID:AB_305055), rat anti-mouse CD8 ( 537 
1:150 dilution, eBioscience, Cat# 14-0808-82, RRID: AB_2572861) and rat anti-mouse Foxp3 (1:100 538 
dilution, eBioscience, Cat# 12-5773-80, RRID: AB_465935). 539 
 540 
Immunofluorescence staining 541 
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Paraffin-embedded stomach sections were dewaxed, rehydrated and antigen-retrieval was 542 
performed by heating in EDTA buffer (pH9) for 15 min in microwave pressure cooker. Section were 543 
incubated for 1 hour at room temperature with goat anti-mouse IL-33 (1:150 dilution, R&D Systems, 544 
Cat# AF3626, RRID:AB_884269) and then for 1 hour with AlexaFluor 568-conjugated donkey anti-545 
goat secondary antibody (Molecular Probes Cat# A-11057, RRID:AB_142581). After counter staining 546 
with spectral DAPI (1:200 dilution, PerkinElmer, Cat# FP1490) for 5 min, sections were mounted with 547 
Vectashield mounting solution (VECTORlabs, Cat# H-1400). Imaging was preformed with a Vectra 3.0 548 
Automated Quantitative Pathology Imaging System (PerkinElmer, Cat# CLS142338) and 549 
representative images were produced using PhenochartTM v1.0.4 software (PerkinElmer). 550 
 551 
Quantification 552 
For quantification of mast cell numbers at least three fields of view (10x ocular) of three Toluidine 553 
Blue section per mouse were counted, submucosal area was measured and data represented as 554 
mast cells number/area tissue. Similarly, for quantification of CD3, BrdU and Apoptag staining, either 555 
entire tumors or three fields of view of three sections were counted and analyzed comparing to 556 
tissue area.  557 
F4/80, CD31, B220 and Hypoxia immune-staining was quantified using Metamorph software 558 
(Molecular Devices) or Fiji scripts (ImageJ, htps://Fiji.sc/) determining percentage positive area per 559 
area tissue. 560 
 561 
Isolation of gastric epithelial cells, immune cells and flow cytometric analysis 562 
Glandular stomachs or antral tumors were dissected, cut into very small pieces and incubated at 563 
37°C fro 30min in Ca2+- and Mg2+-free HBSS medium plus 2.5% FCS and 1 mM EDTA with 564 
gentle shaking. Then samples were vortexed for 30 seconds and the supernatants containing 565 
intraepithelial lymphocytes were separated from the tissue fragments and kept on ice. The 566 
remaining tissue samples were further digested in Collagenase/Dispase (Roche) and DNase I 567 
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(Roche) in Ca2+- and Mg2+-free HBSS medium plus 2% FCS for 45 minutes at 37°C under 568 
continuous rotation. Samples were vortexed for 30 seconds once during incubation and once 569 
after the incubation. Afterwards, cell suspensions from both incubations were pooled, filtered 570 
and washed in PBS plus 5% FCS for analysis by flow cytometry.  571 
Single cell suspensions were stained for cell surface markers (listed below) and cell viability was 572 
controlled with propidium iodide (ThermoFischer Scientific, Cat# P3566) or SYTOXBlue 573 
(ThermoFischer Scientific, Cat# S34857) staining. Cell sorting was performed with an Aria II cell 574 
sorter (BD Bioscience). All cell-type specific flow cytometric gating strategies are presented as a 575 
Supplementary Figure (Supplementary Fig. 8a-e). Mast cells sorting: From CD45+EpCam- cell 576 
population the CD11b- cells were selected, then finally the c-Kit+FceRI+ population represents the 577 
mast cells. Macrophage sorting: From CD45+EpCam- cells, the F4/80HighCD11b+ population was 578 
selected and back-gated to confirm that the selected macrophage population was Ly6C-Ly6G-.  579 
The following fluorochrome-conjugated antibodies were used for flow cytometric cell sorting and 580 
analysis: CD16/CD32 (1/100 dilution, clone 93, Cat# 14-0161-86), EpCAM-FITC (1/400 dilution, clone 581 
9CA ,Cat# 11-5791-82), Ly6c-eF450 (1/300 dilution, HK1.4, Cat# 48-5932-82), F4/80-PE-Cy7 (1/400 582 
dilution, BM8, Cat# 25-4801-82), St2-PerCP-eFluor710 (1:200 dilution, clone RMST2-2, Cat# 46-9335-583 
82), Foxp3-PE (1/200 diltuion, clone FJK-165, Cat# 12-5773-82), Gata3-PE (1/200 dilution, clone 584 
TWAJ, Cat# 12-9966-42), FceR1-PE-Cy7 (1/300, clone 36951, Cat# 25-5898-82), CD3-PE-Cy7 (1/1000, 585 
145-2C11, Cat# 25-0031-82) all from Ebioscience; CD11b-PE (1/400 dilution, M1/70, Cat# 553311), 586 
Ly6g (1/300 dilution, 1A8, Cat# 560602) from BD Pharmingen and CD45.2-A700 (1/400 dilution, 587 
clone S450-15-2), CD4 (1/50 dilution, clone GK 1.5), CD11b-PB (1/400 dilution, M1/70), c-Kit-APC 588 
(1/200, ACK-2)  from WEHI monoclonal antibody facility.  589 
 590 
Isolation and stimulation of bone marrow-derived macrophages 591 
Bone marrow was collected from the femur and tibia of mice by flushing with sterile PBS. Cells were 592 
washed with PBS twice and were filtered through a 100 mm sieve. Resulting cell suspensions were 593 
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cultured in DMEM supplemented with 10% (v/v) FCS and L929 conditioned medium for seven days 594 
with fresh media changes every second day until fully differentiated into bone marrow-derived 595 
macrophages (BMDM). After re-seeding of cells,  alternative macrophage polarization was 596 
conducted  by stimulation with IL-4 (20 ng/ml, Preprotech) and IL-13 (20 ng/ml, Preprotech) for one 597 
day. 598 
 599 
Cytokine bead array 600 
50,000 isolated gastric gp130FF mast cells were cultured in 96 well plates for 3 hrs in 30 ng/mL IL-33. 601 
Supernatants were collected, diluted 1:2 in assay buffer and assayed for cytokine concentration 602 
using the Bio-Rad Bioplex cytokine bead assay (Bio-Rad Mouse 23-Plex Panel M60009RDPD) strictly 603 
according to manufacturer’s instructions. 604 
 605 
Bone marrow-derived mast cell adaptive transfer assay 606 
Mast cells were generated from bone marrow from either gp130FF;ST2+/+ or gp130FF;ST2-/- mice . 607 
Bone marrow was extracted and cells were maintained in IL-3-containing culture medium for several 608 
weeks until >95% pure bone marrow-derived mast cell (BMMC) cultures were established. Purity of 609 
BMMCs ( FceR1+, c-Kit+) was determined via flow cytometry. For BMMC transplantation assay, 610 
syngeneic BMMC from the same colony as the host mice were used. Either gp130FF;ST2+/+ or 611 
gp130FF;ST2-/- BMMCs were injected into the tail vein of gp130FF;ST2-/- mice. Each mouse received 612 
107 BMMC at 5, 8 and 11 weeks of age and final tumor analysis was performed at 14 weeks of age. 613 
 614 
Gastric organoid assay 615 
Antral tumors from gp130FF mice were used to establish tumor-epithelial organoids. Organoids were 616 
established and maintained in IntestiCultTM Organoid Growth Medium (StemCell Technologies) 617 
according to manufacturers protocols. Established organoids were stimulated with 100 ng/ml IL-11 618 
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or PBS control for 4 h and then processed for gene expression analysis via qPCR. For assessment of 619 
organoid growth, PBS or IL-11 stimulated organoids were monitored over 4 days.  620 
 621 
RNA isolation and quantitative RT-PCR 622 
Total RNA was extracted from frozen tissue samples using Trizol®Reagent (life technologies, Cat# 623 
15596026) and cDNA was prepared from 2 µg RNA using the High capacity cDNA Reverse 624 
Transcription kit (Applied Biosystems, Cat# 4368813) according to the manufacturer’s protocol.  625 
From isolated gastric mast cells and from FACS sorted macrophages, RNA was extracted using the 626 
RNeasy Plus Micro Kit (QIAGEN, Cat# 74034) and cDNA synthesis was performed with 627 
ThermoScriptTM RT-PCR System (Invitrogene, Cat# 11146-024) according to the manufacturer’s 628 
instructions. 629 
Quantitative RT-PCR analyses were performed in technical triplicates with SensiMix SYBR kit (Bioline, 630 
Cat# QT605-20)) using the ViiA™ 7 Real Time PCR System (life technologies). Further details and the 631 
sequences of the used oligonucleotides are described in the supplementary methods and 632 
Supplementary Table S1.  633 
 634 
Kaplan-Meyer survival analysis 635 
All Kaplan-Meyer survival analysis was performed with KMplot (KMplot.com) 54. Data from 179 636 
intestinal-type gastric cancer patient were analyzed and following settings were applied: Probes= all 637 
probe sets, Laurens classification=intestinal -type, Data sets included: GSE14210, GSE15459, 638 
GSE22377, GSE29272, GSE51105, but excluding GSE62254 (as recommended; due to markedly 639 
different survival and shifted expression compared to the other data sets). All other settings were 640 
kept as default. 641 
 642 
Statistics 643 
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Unless otherwise stated, data are presented as mean values ± standard error of the mean (M±SEM). 644 
Exact n values are depicted for every data set in the figure legends and they are always true 645 
biological replicates, not technical replicates. All data sets were tested for normality with Shapiro 646 
Wilk normality test. Comparisons between two mean values were performed by two-tailed unpaired 647 
Student’s t test using Prism6 software (GraphPad Software, California, USA). When data sets had 648 
significantly different standard deviations according to Prism’s F-test of variances,  Welsh correction 649 
was applied. T-test t values and corresponding degree of freedom (df) are given in figure legends. 650 
For comparisons of more than two groups one-way ANOVA test was performed with multiple 651 
comparison correction (either Tukey or Bonferroni). ANOVA F values are depicted in each figure 652 
legend as F (DFn, Dfd), where DFn is the degree of freedom nominator and Dfd the degree of 653 
freedom denominator.  P values of less than 0.05 were considered statistically significant. 654 
 655 
Sample size determination 656 
G*power3.1 software was used to estimate the minimal required sample sizes. Based on previous 657 
mean values and SD from previous studies using the gp130FF mouse model, we calculated a minimal 658 
sample size for 8 mice per group, when the mean difference is 40% and the SD’s 20% (unpaired two-659 
tailed t-test; α=0.05, Power=0.95). Due to difference in availability and frequency of target 660 
genotypes born, the number of mice analyzed between cohorts differed. Sample size for subsequent 661 
analysis of tissue section staining was limited to number available, as tissues were required for 662 
several downstream processes including FACS analysis, RNA and protein expression in addition to 663 
histological and immunohistochemical analysis. 664 
 665 
Randomization 666 
No formal randomization procedure was performed. However, for genetic mouse experiments, 667 
littermates were used to compare different target genotype mice. For in vivo treatment 668 
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experiments, different treatment groups were equally distributed between mouse litters and mouse 669 
cages as well as female and male ratio were kept at 1:1.  670 
 671 
Data exclusion 672 
No data was excluded after commencement of quantification. In a few cases, tissue slides were 673 
excluded from downstream analysis due to strong background staining or absence of tumor tissue. 674 
These slides were excluded from analysis before commencement of quantification and without 675 
knowledge of genotypes/treatment details (aka blinded). 676 
 677 
Blinding 678 
Assessors were blinded for determining tumor masses and numbers and for quantification of histo- 679 
and immunohistochemical staining. Blinding was achieved through labeling minimized to mouse IDs. 680 
Genotypes and treatment were only linked back to the mouse ID after completion of quantification. 681 
 682 
 683 
Data availability 684 
The Stat3 Chromatin Immunoprecipitation-Sequencing (ChIP-Seq) data have been deposited in the 685 
NCBI gene expression omnibus (GEO) under the accession code GSE48285 686 
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48285]. The source data underlying Figs 687 
1b, 1d, 2b-h, 3b-e, 4b-e, 5a-c, 6a, 6c, 6d, 6f, 7a-g, 8a and Supplementary Figs 1b, 2a, 2b, 2g, 2i, 3d, 688 
5a, 5b, 5g, 5h, 6e, 6f are provided as a Source Data file. All the other data supporting the findings of 689 
this study are available within the article and its supplementary information files and from the 690 
corresponding author upon reasonable request. A reporting summary for this article is available as a 691 
Supplementary Information file.  692 
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Fig. 1 Submucoal mast cell numbers are increased in gastric cancer in mice and humans 887 
a Representative cross-sections of stomachs of 100 day old gp130 mutant mice of the indicated 888 
genotype and stained with Toluidine Blue showing the affected antrum (AN) and antral tumor 889 
(AT) respectively. Mast cells appear purple (arrows). Scale bars = 50 µm. 890 
b Quantification of submucosal mast cell in sections depicted in A. n = 7 mice per cohort obtained 891 
from two independent experiments, One-way ANOVA F (DFn = degree of freedom nominator,  892 
Dfd = degree of freedom denominator) = 34.96 (3, 24).  893 
c Representative sections of Toluidine Blue-stained biopsy cores of human gastric cancer (GC) and 894 
adjacent submucosa and of normal stomach submucosa . Scale bars = 50 µm. 895 
d Quantification of submucosal mast cell in sections depicted in C. Each symbol represents an 896 
individual patient biopsy from submucosa of normal (N; n=22), gastritis (Gas; n=2), intestinal 897 
metaplasia (IM; n=4), diffuse (Dif; n=8), mixed (Mix; n=3), and intestinal-type (Int; n=8) gastric 898 
cancer. One-way ANOVA F (DFn, Dfd) = 5.809 (5, 41)  899 
 900 
Data are represented as mean ± SEM, with p < 0.05 considered significant. Source data are provided 901 
as a Source Data file. See also related Supplementary Fig. 1. 902 
  903 
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Fig. 2 Gastric tumor burden is reduced in mast cell–deficient gp130FF tumor mice  904 
a Representative whole mounts of pinned out stomachs, from 100 day old gp130FF;c-Kit+/+ and mast 905 
cell-deficient gp130FF;c-KitW-sh/W-sh mice. Scale bars = 1mm. 906 
b Quantification of total tumor burden per mouse as in A. Each symbol represents an individual 907 
mouse. One-way ANOVA F (DFn, Dfd) = 25.97 (2, 24). 908 
c Enumeration of total tumor number and tumor size distribution as in A from gp130FF;c-Kit+/+ 909 
(n=14) and gp130FF;c-KitW-sh/W-sh mice (n=11). One-way ANOVA F (DFn, Dfd) = 24.59 (7, 92). 910 
d Quantification of CD31, Hypoxy-probe (hypoxia), BrdU (proliferation) or ApopTag (apoptosis) on 911 
immunostained gastric tumors sections.. Number of mice (n) for CD31: FF;c-Kit+/+ n = 7, FF;c-KitW-912 
sh/W-sh n = 11 with ANOVA F (DFn, Dfd) = 7.075 (3, 34); Hypoxy-probe: FF;c-Kit+ n = 5, FF;c-KitW-sh n 913 
= 6 with t-test+Welsh correction’s t (df) = 2.55 (5.256); BrdU: FF;c-Kit+ n = 3, FF;c-KitW-sh n = 4 with 914 
t-test’s t (df) = 4.905 (5); Apoptosis: FF;c-Kit+ n = 4, FF;c-KitW-sh n = 6 with t-test’s t (df) = 0.89 (8). 915 
e Quantification of total tumor burden per mouse of mast cell proficient FF;MCwt (genotypes: 916 
FF;Cpa3-Creneg;Mcl1fl/fl and FF,Cpa-Cre;Macl1+/+) and mast cell deficient FF;MCdef (genotype: 917 
FF;Cpa3-Cre;Mcl1fl/fl) mice. t-test’s t (df) = 6.72 (24). 918 
f Enumeration of the tumor number per mouse of FF;MCwt (n = 17  mice) and mast cell-deficient 919 
FF;MCdef (n = 9 FF;Cpa3-Cre;Mcl1fl/fl mice) (One-way ANOVA F (DFn, Dfd) = 23.25 (7, 96). 920 
g CD31 angiogenic staining quantification of stomachs from e,f. FF;MCwt (n = 8 mice) and FF;MCdef 921 
(n = 5) with One-way ANOVA F (DFn, Dfd) = 6.79 (3, 22). 922 
h Quantification of total tumor burden in gp130FF mice after 6 weeks administration of cromolyn 923 
(mast cell degranulation inhibitor) or vehicle. Each symbol represents an individual mouse and 924 
data was generated in three independent experiments. t-test’s p value is shown and t (df) = 2.313 925 
(18). 926 
 927 
Data are represented as mean ± SEM, with p values p < 0.05, being considered significant. Source 928 
data are provided as a Source Data file. See also related Supplementary Fig 2.  929 
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Fig. 3 Mast cell depletion reduces macrophage infiltration in gastric tumors of gp130FF mice  930 
a Representative images of tissue sections immunostained for macrophages (F4/80), B cells (B220) 931 
or T cells (CD3, CD8, Foxp3) in gastric tumor sections of gp130FF;c-Kit+/+ and mast cell-deficient 932 
gp130FF;c-KitW-sh/W-sh mice. Arrows indicate specific positive cell staining; scale bars = 100µm. 933 
b Quantification of F4/80, B220 or CD3 expressing cells in tumor and tumor-associated submucosal 934 
layers of sections from A. (F4/80: n = 6 each group, one-way ANOVA F (DFn, Dfd) = 13.43 (3, 20); 935 
B220: n = 6 each group, one-way ANOVA F (DFn, Dfd) = 3.782 (3, 20); CD3: FF;c-Kit+/+ n=6, FF;c-936 
KitW-sh/W-sh n = 5, one-way ANOVA F (DFn, Dfd) = 11.55 (3, 18); CD8: FF, c-Kit+/+ n = 8, FF;c-KitW-sh/W-937 
sh n = 6, t-test t (df) = 0.71 (12); Foxp3: FF, c-Kit+/+ n = 6, FF;c-KitW-sh/W-sh n = 8, t-test t (df) = 0.33 938 
(12). Data from two independent experiments were analyzed. 939 
c F4/80+ cells frequency in stomach submucosa and tumors of FF;MCwt mice (n = 9) and mast cell-940 
deficient FF;MCdef mice (n = 7 FF;Cpa3-Cre;Mcl1fl/fl) (One-way ANOVA F (DFn, Dfd) = 10.81 (3, 28). 941 
d Quantification of F4/80+ cells in unaffected antrum (AN) or antrum tumor (AT) in submucosa or 942 
mucosa of mice of the indicated genotype. All groups n = 4. Submucosal: one-way ANOVA F (DFn, 943 
Dfd) = 10.12 (3, 12); Mucosal: one-way ANOVA F (DFn, Dfd) = 5.086 (3, 12). 944 
e Quantification of F4/80+ cells in unaffected antrum (AN) or antrum tumors (AT) in submucosa or 945 
mucosa of mice from the Tg(Tff1-CreERT2);Pik3caH1047R/+;Ptenfl/fl strain that either harbor (Cre+) or 946 
lack (Cre-) the Tff1-CreERT2 driver. Cre- AN n = 4 , Cre+ AN and Cre+ AT n = 5 for both. Analyses 947 
from two independent experiments. Submucosal: one-way ANOVA F (DFn, Dfd) = 10.52 (2, 11); 948 
Mucosal: one-way ANOVA F (DFn, Dfd) = 7.485 (2, 11). 949 
 950 
Data are represented as mean ± SEM, with p values p < 0.05 considered being significant. Source 951 
data are provided as a Source Data file. See also related Supplementary Fig. 3.  952 
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Fig. 4 Tumor burden in gp130FF mice diminishes upon macrophage depletion  953 
a Representative whole mount of stomachs from 100d old mice of the indicated genotype. Scale 954 
bar = 1 mm. 955 
b Quantification of total tumor burden per mouse as in A. Each symbol represents an individual 956 
mouse. Due to ill health some gp130F/F;Csf1r-/- mice had to be analyzed before the 100 day 957 
endpoint; average mouse age per groups were: gp130F/F;Csf1r+/+ 88.2d, gp130F/F;Csf1r+/- 90.4 days 958 
and gp130F/F;Csf1r-/- 81.6 days. One-way ANOVA F (DFn, Dfd) = 27.55 (2, 27). 959 
c Quantification of mast cell density in antral submucosa of indicated genotype was performed 960 
with gp130F/F;Csf1r+/+ n = 9 and gp130F/F;Csf1r-/- n = 5 biological samples from two independent 961 
experiments (t-test t (df) = 0.262 (12). 962 
d Assessment of total tumor burden in gp130FF mice after 6weeks administration of clodronate (50 963 
μl of a clodrosome solution containing 5 mg/ml clodronate) or vehicle. Each symbol represents an 964 
individual mouse; data from two independent experiments (t-test t (df) = 2.622 (11)). 965 
e Quantification of F4/80, CD31, ApopTag or Toluidine Blue (for detection of mast cells) stained 966 
sections of gastric tumors (T) and tumor-associated submucosa (SM) from gp130FF mice of the 967 
indicated treatment cohort. F4/80: all n = 5, one-way ANOVA F (DFn, Dfd) = 27.17 (3, 16); CD31: n 968 
= 6 (SM tissues), n = 5 (T tissues), one-way ANOVA F (DFn, Dfd) = 18.15 (3, 18); apoptotic cells: n = 969 
4 (both groups), t-test t (df) = 0.27 (6); mast cells: n = 8 (Vehicle) and n = 7 (Clodronate), t-test t 970 
(df) = 0.73 (13). 971 
Data are represented as mean ± SEM, with p values p < 0.05 considered being significant. Source 972 
data are provided as a Source Data file. See also related Supplementary Fig. 4. 973 
 974 
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Fig. 5 Pharmacological macrophage targeting and macrophage polarization in gp130FF tumors 975 
a Total tumor burden in gp130FF mice was quantified either acutely after a 4 weeks treatment 976 
period with PLX3397 (Csf1r/c-Kit/Flt3 tyrosine kinase receptor inhibitor) or vehicle or after a 977 
4weeks treatment-free follow-up period. Each symbol represents an individual mouse. Data from 978 
three independent experiments are presented. t-test t (df) = 5.23 (14). 979 
b Quantification of F4/80, CD31, Hypoxyprobe or Toluidine Blue stained sections of submucosa 980 
(SM) or gastric tumors (T) of gp130FF mice of the indicated acute treatment cohort. F4/80: n = 5 981 
(Vehicles) and n = 6 (PLX3397), one-way ANOVA F (DFn, Dfd) = 12.34 (3, 18); CD31: n = 6, one-way 982 
ANOVA F (DFn, Dfd) = 18.33 (3,20); hypoxic tissue: n = 3, t-test with Welch’s correction t (df) = 983 
2.53 (2); mast cells: n = 8 (both groups), t-test with Welch’s correction t (df) = 5.59 (9.27)..  984 
c qPCR expression analysis of genes associated with alternative activation (Arg1, Fizz1, Mrc1), 985 
classical activated (Nos2 ) and angiogenesis (Vegfa) of purified F4/80+ tumor associated 986 
macrophages (FF Tum) or following stimulation of bone marrow-derived macrophages (BMM) 987 
from wild-type mice and stimulated either with vehicle (wt BMM) or with IL-4/IL-13 (20 ng/ml) to 988 
induce an alternative activated endotype (M2 BMM). n = 3 mice. Hash indicates that expression 989 
was below detection limit. Arg1: t-test t (df) = 3.8 (4);  Fizz1: t-test t (df) = 2.39 (4); Mrc1: t-test t 990 
(df) = 4.69 (4); Vegfa: t-test t (df) = 3.96 (4).  991 
Data are represented as mean ± SEM, with p values p < 0.05 considered being significant. Source 992 
data are provided as a Source Data file. See also related Supplementary Fig. 4. 993 
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Fig. 6 IL-33 expression in gastric tumors of gp130FF mice and mast cell activation analysis  994 
a qPCR expression analysis of Il33 and full-length St2 (Il1rl1) genes associated with hematopoietic 995 
(CD45+; EpCam-) and epithelial (EpCam+; CD45-) cells purified from unaffected antrum (AN) or 996 
antrum tumors (AT) from wild-type and gp130FF (FF) mice. Data are normalized to Gapdh and 997 
plotted as relative expression to CD45+;EpCAM- WT AN expression. n = 5 mice. Il1rl1 expression in 998 
EpCam+; CD45- cells was for several samples below detection limit., Data was pooled from two 999 
independent experiments. For IL33 data, one-way ANOVA was performed with F (DFn, Dfd) = 1000 
2.871(5, 22); 1001 
b Immunofluorescence staining for IL-33 in stomachs of tumor bearing gp130FF mice with insets 1002 
referring to unaffected antrum (I), submucosal-tumor junction (II), tumor core (III) and tumor 1003 
edge (IV). Stomachs from Il33-/- mice were used for specificity controls. Scale bars = 200 µm. 1004 
c Multiplex cytokine analysis of supernatant of FACS-purified tumor-associated mast cells 1005 
stimulated with IL-33 (30 ng/ml) for 3 h. Data are shown only for factors with >3 fold increase 1006 
relative to unstimulated control cultures. n=4 from four independent experiments.  1007 
d qPCR gene expression analysis in FACS-purified tumor-associated mast cells stimulated with IL-33 1008 
(30 ng/ml) for 3 h or vehicle. n=4 from four independent experiments. Ccl2: t-test t (df) = 3.61 (6); 1009 
Ccl3: t-test t (df) = 3.2 (3.09); Ccl7: t-test t (df) = 2.84 (6); Vegfa: t-test t (df) = 2.45 (6). 1010 
e Representative images of organoids derived from antral tumors (AT) of gp130FFmice stimulated 1011 
either with PBS or IL-11 (100 ng/ml for 2 days. Scale bar=200µm. 1012 
f Il33 gene expression analysis of gp130FF tumor-derived epithelial organoids either stimulated 1013 
with IL-11 (100 ng/ml) or with PBS for 4 h. For comparison expression of Stat3-target gene, Socs3, 1014 
was also analyzed. n=5 from two independent experiments. Stat3: t-test t (df) = 4.96 (4.42); 1015 
Socs3: t-test t (df) = 5.6 (4.48). 1016 
 1017 
Data are represented as mean ± SEM, with p values p < 0.05 considered being significant. Source 1018 
data are provided as a Source Data file. See also related Supplementary Fig. 5. 1019 
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Fig. 7 Tumor burden is reduced in St2 receptor-deficient gp130FF mice 1020 
a Quantification of total tumor burden in 100 day old mice of the indicated genotype. Each symbol 1021 
represents an individual mouse. One-way ANOVA was performed with F (DFn, Dfd) = 11.83 (2, 1022 
48). 1023 
b Enumeration of total tumor number from mice in A, and of tumors following classification 1024 
according to their size. n = 12 (FF,St2+/+), n = 20 (FF,St2+/-) and n = 19 (FF,St2-/-) mice. One-way 1025 
ANOVA was performed with F (DFn, Dfd) = 22.79 (11, 192). 1026 
c Quantification of Toluidine Blue (for detection of mast cells; submucosal tissue), F4/80 and CD31 1027 
stained sections of gastric tumors of mice of the indicated genotype. Mast cells: n = 10 mice, : t-1028 
test t (df) = 4.25 (18); F4/80: n = 8 (FF;St2+/+), n = 9 (FF;St2-/-), one-way ANOVA F (DFn, Dfd) = 1029 
27.52 (3,29); CD31: n = 6 (Submucosa) n = 5 (Tumor), one-way ANOVA F (DFn, Dfd) = 13.6 (3,19). 1030 
d qPCR expression analysis of chemokines expressed by FACS-purified tumor-associated mast cells 1031 
from stomachs of either FF;St2+/+ or FF;St2-/- mice. All n = 4 from two independent experiments. 1032 
Csf2: .t-test t (df) = 3.81 (6); Ccl3: t-test t (df) = 3.97 (6); Ccl7: t-test t (df) = 0.88(6); Il6: : t-test t 1033 
(df) = 4.02 (6); 1034 
e,f Flow cytometric analysis of unaffected antrum (AN) and antrum tumors (AT) of indicated 1035 
genotype for the frequency of ILC2 cells (lineage-,Cd11b-,Gata3+), Tregs (Foxp3+, CD4+) and 1036 
proportion of St2+ cells within these cell types. FF;St2+/+ n=7 and FF;St2-/- n = 6, from two 1037 
independent experiments. ST2+/ILC2: t-test t (df) = 4.39 (12); ST2+/Treg: t-test t (df) = 0.98 (12). 1038 
g Enumeration of total tumor burden at 14 weeks of age of FF;St2-/- host mice, which received tail 1039 
vein injections of either FF;St2-/- or FF,St2+/+ bone marrow-derived mast cells (BMMC) (n=8 mice 1040 
per group). Mann-Whitney test was performed with Mann-Whitney U=11.5.  1041 
 1042 
Data are represented as mean ± SEM, with p values p < 0.05 considered being significant. Source 1043 
data are provided as a Source Data file. See also related Supplementary Fig. 6. 1044 
Page 42 
Fig. 8 Kaplan-Meier analysis for an IL-33 - mast cell activation gene expression signature 1045 
a Expression analysis of genes associated with IL-33 dependent mast cell activation derived from 1046 
the DERRICO gastric data set (GEO: GSE13911, extracted from oncomine.org) and comparing 1047 
normal gastric mucosa (n=31) and gastric intestinal-type adenocarcinoma (n = 29). The p-value 1048 
for the genes is p < 0.05 except where indicated. 1049 
b-d Kaplan-Meyer Survival analysis was performed for human intestinal-type gastric cancer (iGC) 1050 
with IL-33/ mast cell activation signature consisting of CCL2, CCL3, CCL4, IL1a, IL6, CSF2, and CCL7 1051 
(b), with alternative activation macrophage expression signature (CD163, CD204, MARCO, ARG1) 1052 
(c) and classical activation macrophage expression signature (NOS2A, HLA-DRA, CD80, CD86, 1053 
CD169) (d).  1054 
e Schematic illustration of the proposed gastric cancer growth promoting IL-11/IL-33/mast 1055 
cell/TAM signaling axis. 1056 
Source data are provided as a Source Data file. See also related Supplementary Fig. 7. 1057 
 1058 
 1059 
Mast cells within the tumour microenvironment have controversial roles. Here, the authors show, 1 
using genetic mouse models, that in gastric cancer, mast cells at the periphery of the tumours are 2 
activated via cancer cell produced-IL33 and promote tumorigenesis by recruiting macrophages 3 
within the tumours 4 
d        Mast cells in human gastric cancer
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